Literature DB >> 15723242

Increased DNA breaks and up-regulation of both G(1) and G(2) checkpoint genes p21(WAF1/CIP1) and 14-3-3 sigma in circulating leukocytes of glaucoma patients and vasospastic individuals.

H Moenkemann1, J Flammer, K Wunderlich, W Breipohl, H H Schild, O Golubnitschaja.   

Abstract

OBJECTIVE: Vascular disorder leading to local ischemia/reperfusion has been shown to play an important role in the glaucomatous damage. A decreased expression level of XPGC-gene has been found in circulating leukocytes of normal-tension glaucoma patients. Although decreased activity of XPGC-gene leads to insufficient DNA-repair, no leukopenia has been observed in glaucoma. Molecular mechanisms ensuring cell survival have not been elucidated yet for glaucoma with vascular disorder.
MATERIAL AND METHODS: Using the ex vivo optical imaging method of alkaline "comet assay" comparative quantification of DNA breaks was performed in circulating leukocytes of non-glaucomatous non-vasospastic and vasospastic individuals as well as both normal-tension and high-tension glaucoma patients. Relative expression levels of the anti-apoptotic factors P21(WAF1/CIP1) and 14-3-3 sigma were investigated in all groups tested. RESULTS AND
CONCLUSIONS: The quantification of P21(WAF1/CIP1) showed the highest expression rates in high-tension glaucoma patients which were significantly higher than those in all other groups tested. The highest expression rates of 14-3-3 sigma were found in both groups of glaucoma patients. These expression levels correlated well with DNA breaks measured. Since the expression of P21(WAF1/CIP1) in leukocytes was shown to be crucial for their survival under stress conditions, we suppose further that the up-regulation of this gene is the key event in the survival mechanisms of leukocytes in glaucoma accompanied with vascular disorder. The p21(WAF1/CIP1) gene should be further taken into consideration as a potential marker, the up-regulation of which in circulating leukocytes of vasospastic individuals may indicate an increased risk for the developing glaucoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15723242     DOI: 10.1007/s00726-005-0169-x

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  13 in total

1.  In vitro expression levels of cell-cycle checkpoint proteins are associated with cellular DNA repair capacity in peripheral blood lymphocytes: a multivariate analysis.

Authors:  You-Hong Fan; Zhibin Hu; Chunying Li; Li-E Wang; Zhaozheng Guo; Yawei Qiao; Li Zhang; Wei Zhang; Li Mao; Qingyi Wei
Journal:  J Proteome Res       Date:  2007-03-16       Impact factor: 4.466

2.  [Glaucoma and oxidative stress. Determination of malondialdehyde--a product of lipid peroxidation].

Authors:  C Faschinger; O Schmut; C Wachswender; G Mossböck
Journal:  Ophthalmologe       Date:  2006-11       Impact factor: 1.059

3.  The primary vascular dysregulation syndrome: implications for eye diseases.

Authors:  Josef Flammer; Katarzyna Konieczka; Andreas J Flammer
Journal:  EPMA J       Date:  2013-06-07       Impact factor: 6.543

Review 4.  Oxygen and blood flow: players in the pathogenesis of glaucoma.

Authors:  Maneli Mozaffarieh; Matthias C Grieshaber; Josef Flammer
Journal:  Mol Vis       Date:  2008-01-31       Impact factor: 2.367

5.  Vasospastic individuals demonstrate significant similarity to glaucoma patients as revealed by gene expression profiling in circulating leukocytes.

Authors:  Kristina Yeghiazaryan; Josef Flammer; Selim Orgül; Kerstin Wunderlich; Olga Golubnitschaja
Journal:  Mol Vis       Date:  2009-11-14       Impact factor: 2.367

6.  Role of MYOC and OPTN sequence variations in Spanish patients with primary open-angle glaucoma.

Authors:  Francisco Lopez-Martinez; Maria-Pilar Lopez-Garrido; Francisco Sanchez-Sanchez; Ezequiel Campos-Mollo; Miguel Coca-Prados; Julio Escribano
Journal:  Mol Vis       Date:  2007-06-14       Impact factor: 2.367

7.  Key molecular pathways affected by glaucoma pathology: is predictive diagnosis possible?

Authors:  Olga Golubnitschaja; Kristina Yeghiazaryan; Josef Flammer
Journal:  EPMA J       Date:  2010-06-29       Impact factor: 6.543

8.  Predictive molecular profiling in blood of healthy vasospastic individuals: clue to targeted prevention as personalised medicine to effective costs.

Authors:  Kristina Yeghiazaryan; Josef Flammer; Olga Golubnitschaja
Journal:  EPMA J       Date:  2010-06-29       Impact factor: 6.543

9.  Comet assay analysis of single-stranded DNA breaks in circulating leukocytes of glaucoma patients.

Authors:  M Mozaffarieh; A Schoetzau; M Sauter; M Grieshaber; S Orgül; O Golubnitschaja; J Flammer
Journal:  Mol Vis       Date:  2008-08-29       Impact factor: 2.367

10.  The effect of ranibizumab versus photodynamic therapy on DNA damage in patients with exudative macular degeneration.

Authors:  M Mozaffarieh; A Schötzau; T Josifova; Josef Flammer
Journal:  Mol Vis       Date:  2009-06-13       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.